Purchase Order 75N91023P00535

Award Date 6/27/23
Potential Completion Date 6/26/25
Potential Value $249K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Cancer Institute (NCI) awarded a $249,814 firm fixed-price purchase order contract to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to establish the US Pediatric Proton and Photon Therapy Cohort. This retrospective cohort study will compare the risks and benefits of proton therapy versus photon therapy for pediatric cancer patients. The contractor will retrieve de-identified clinical and treatment data...
This is a $250,000.00 firm fixed-price purchase order awarded by the National Cancer Institute (NCI) to Baylor College of Medicine for the US Pediatric Proton and Photon Therapy Cohort study. The contract, which has no set-aside designation, requires Baylor to retrieve de-identified clinical and treatment data from existing medical records of eligible pediatric cancer patients treated with proton or photon therapy at their institution. This data will be used to evaluate the risks and benefits of...
This is a firm-fixed-price contract awarded by the National Cancer Institute (NCI) to Princeton Procure Management LLC (Procure Proton Center) for $150,150 to provide medical record abstraction services for a study comparing pediatric proton and photon radiotherapy. The 14-month contract, which starts on or about November 1, 2024, is part of NCI's Pediatric Proton and Photon Therapy Comparison Cohort program. The contractor will retrieve de-identified clinical and treatment data from medical...
This is a firm-fixed-price purchase order awarded by the National Cancer Institute to The Washington University for $249,997 to provide medical record abstraction services in support of a study comparing pediatric proton and photon radiation therapy. The 14-month contract does not have a set-aside designation. The services will involve retrieving de-identified clinical and treatment data from medical records of pediatric cancer patients treated with proton or photon radiotherapy. This contract...
This firm fixed price purchase order awarded by the National Institutes of Health's National Cancer Institute to Mayo Clinic seeks to obtain clinical data on pediatric cancer patients treated with proton therapy or photon therapy. The goal is to retrieve existing diagnosis and treatment data from medical records of eligible patients treated since January 2007 at contractor institutions and enter de-identified data into a secure database to serve as a comparison cohort for a US Pediatric Proton...
The National Cancer Institute (NCI) awarded a $293,970 firm fixed-price purchase order to the University Health Network (UHN), doing business as the Toronto General And Western Hospital Foundation, to retrieve existing clinical and treatment data for at least 500 pediatric cancer patients treated with photon therapy since 2007. This data will be used to evaluate photon therapy as a cancer treatment for pediatric patients as part of the U.S. Pediatric Photon Therapy Comparison Cohort Study. The...
This federal contract award was made by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson), a component of the University of Texas System. The contract, valued at $247,116.20, is for the US Pediatric Proton and Photon Therapy Cohort, a retrospective cohort study comparing the risks and benefits of proton therapy versus photon therapy for pediatric cancer patients. MD Anderson will retrieve de-identified clinical and treatment data from existing...
This is a firm fixed-price purchase order awarded by the National Cancer Institute (NCI) to Northwestern University for $250,000 to provide medical record abstraction services for a study comparing pediatric cancer patients treated with proton versus photon radiation therapy. The services will be performed remotely, and the period of performance is a 14-month base period starting around November 1, 2024. This requirement was competed under simplified acquisition procedures without a set-aside...
This is a firm-fixed-price contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (HHS), to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to serve as the Pediatric Proton and Photon Therapy Comparison Cohort Coordinating Center. The $624,994 contract will run from September 2024 to March 2027. The contractor will assemble existing data from medical records for a group of pediatric cancer patients...
The National Institutes of Health's National Cancer Institute awarded a $249,323 firm fixed price purchase order to The General Hospital Corporation Research Management Division, doing business as Massachusetts General Hospital. This contract is to serve as the Pediatric Proton and Photon Therapy Comparison Cohort Coordinating Center. Per the statement of work, the center will coordinate data collection and analysis from multiple pediatric cancer treatment sites comparing outcomes of patients...

The National Cancer Institute (NCI) has awarded a $248,767 firm fixed-price purchase order contract to Proton Doctors Professional Corporation for the US Pediatric Proton and Photon Therapy Cohort, a retrospective cohort study comparing risks and benefits of proton therapy versus photon therapy for pediatric cancer patients. This contract is not set-aside. The goal is to obtain de-identified clinical and treatment data from existing medical records of eligible pediatric patients treated with proton or photon therapy at the contractor's institution. This data will be used to evaluate second cancer risks and other adverse effects between the two radiation therapy modalities. The contract has a period of performance through June 26, 2025 and is based on the federal contract opportunity originally posted in September 2022.

Generated 6/14/24, 9:03 AM